- Piomic Medical closes $25M Growth round led by Swisscanto
Piomic Medical closes $25M Growth round led by Swisscanto
- ReEmerge exits stealth with $37M Series A for brain injury cognitive therapy
ReEmerge exits stealth with $37M Series A for brain injury cognitive therapy
- Johnson & Johnson MedTech reportedly could sell DePuy Synthes to Apollo
Johnson & Johnson MedTech reportedly could sell DePuy Synthes to Apollo
- Boston Scientific invests $1.5B in TAVR developer MiRus
Boston Scientific announced that it invested $1.5 billion in transcatheter aortic valve replacement (TAVR) developer MiRus. Marlborough, Massachusetts–based Boston Scientific now has an equity stake in MiRus worth approximately 34%. The deal also includes an exclusive option to acquire MiRus’ Siegel
- Xeltis gains EU CE mark on positive trial data for vascular access graft
Xeltis has gained a European CE mark for aXess, with 12-month pivotal data of the vascular access graft for haemodialysis demonstrating strong and higher secondary patency versus conventional arteriovenous grafts (AVGs). Xeltis’s aXess is a bioabsorbable graft for haemodialysis that is injected unde
- EmStop initiates IDE study of novel embolic protection device
EmStop announced that it kicked off the CAPTURE-2 FDA investigational device exemption (IDE) study of its embolic protection system (EPS). CAPTURE-2 evaluates the safety and performance of the EPS, an investigational device for cerebral embolic protection designed to capture and remove debris that i
Market Insight
Evidence-Based Deep Dive
Top Picks
Latest MedTech News
Boston Scientific announced that it invested $1.5 billion in transcatheter aortic valve replacement (TAVR) developer MiRus.
Marlborough, Massachusetts–based Boston Scientific now has an equity stake in MiRus worth approximately 34%. The deal also includes an exclusive option to acquire MiRus’ Siegel
Xeltis has gained a European CE mark for aXess, with 12-month pivotal data of the vascular access graft for haemodialysis demonstrating strong and higher secondary patency versus conventional arteriovenous grafts (AVGs).
Xeltis’s aXess is a bioabsorbable graft for haemodialysis that is injected under
EmStop announced that it kicked off the CAPTURE-2 FDA investigational device exemption (IDE) study of its embolic protection system (EPS).
CAPTURE-2 evaluates the safety and performance of the EPS, an investigational device for cerebral embolic protection designed to capture and remove debris that in